THC May Treat Spasticity and Pain Associated with Multiple Sclerosis, According to New Research

The oral administration of Δ9-tetrahydrocannabinol (THC) may treat both spasticity and pain associated with multiple sclerosis.

Multiple SclerosisThis is according to a study being published by the journal Clinical Therapeutics, and e-published ahead of print by the U.S. National Institute of Health.

According to the Mayo Clinic, multiple sclerosis (MS) is a “disease in which the immune system eats away at the protective covering of nerves.” The ailment affects around 200,000 people annually and has no cure. Multiple sclerosis causes many different symptoms, including vision loss, pain, fatigue, and impaired coordination.

The aim of the present study was to “evaluate the efficacy of an oral formulation of Δ9-tetrahydrocannabinol (ECP002A) in patients with progressive multiple sclerosis (MS).”

Read moreTHC May Treat Spasticity and Pain Associated with Multiple Sclerosis, According to New Research

Long-Term Use of Cannabis Spray Effective in Treating Multiple Sclerosis Spasticity, Says Study

A study published last week by the journal European Neurology has found that the long-term use of Sativex, a spray made from the cannabis plant (one part THC, one part CBD), is effectivesativex1 in treating multiple sclerosis spasticity.

According to researchers, the study’s objective was to “provide long-term data on clinical outcomes, tolerability, quality of life and treatment satisfaction for MSS [multiple sclerosis spasticity] patients receiving nabiximols [Sativex] in routine care.”

Read moreLong-Term Use of Cannabis Spray Effective in Treating Multiple Sclerosis Spasticity, Says Study

New Study Finds Cannabinoids An Effective Treatment For Multiple Sclerosis

A new study published in this month’s issue of the journal European Neurology, and published online by the U.S. National Institute of Health,stock2 has found that Sativex – a medicinal spray made from the cannabis plant – is an effective and safe treatment option for “moderate to severe multiple sclerosis spasticity (MSS)”.

According to researchers: “Nabiximols (Sativex®), a cannabinoid-based oromucosal spray, is an add-on therapy for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to other medications. The primary objective was to provide real-life observational data of clinical experience of nabiximols in contrast to formal clinical trials of effectiveness.”

Read moreNew Study Finds Cannabinoids An Effective Treatment For Multiple Sclerosis